BofA Securities Reiterates Buy Rating on Vera Therapeutics (VERA): Vertex data "appears to pose no real threat"
Tweet Send to a Friend
BofA Securities analyst Dina Ramadane reiterated a Buy rating and $66.00 price target on Vera Therapeutics (NASDAQ: VERA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
